Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) traded down NaN during mid-day trading on Friday . The stock traded as low as $3.08 and last traded at $0.00. 5,396,293 shares were traded during mid-day trading, an increase of Infinity from the average session volume of 0 shares.

Several equities research analysts have issued reports on the stock. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $9.00 price target on shares of Synergy Pharmaceuticals in a report on Tuesday, July 18th. CIBC lowered their price target on shares of Synergy Pharmaceuticals from $9.00 to $6.00 and set an “outperform” rating on the stock in a report on Friday, September 8th. HC Wainwright set a $8.00 price target on shares of Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday. Zacks Investment Research raised shares of Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Citigroup Inc. reissued a “sell” rating and issued a $2.50 price target (down previously from $3.20) on shares of Synergy Pharmaceuticals in a report on Wednesday, September 13th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. Synergy Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.90.

The stock’s market cap is $695.11 million. The firm has a 50 day moving average of $2.94 and a 200-day moving average of $3.77.

Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.08). The company had revenue of $2.31 million during the quarter, compared to the consensus estimate of $1.98 million. During the same quarter in the prior year, the firm earned ($0.23) EPS. On average, equities research analysts expect that Synergy Pharmaceuticals, Inc. will post ($1.16) earnings per share for the current year.

In related news, major shareholder Paulson & Co. Inc. sold 26,287 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $3.77, for a total value of $99,101.99. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.80% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank increased its position in shares of Synergy Pharmaceuticals by 7.9% in the first quarter. Amalgamated Bank now owns 24,013 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 1,758 shares during the period. California State Teachers Retirement System grew its position in Synergy Pharmaceuticals by 0.9% in the second quarter. California State Teachers Retirement System now owns 401,730 shares of the biopharmaceutical company’s stock valued at $1,788,000 after acquiring an additional 3,686 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its position in Synergy Pharmaceuticals by 13.9% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 32,018 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 3,900 shares during the last quarter. Principal Financial Group Inc. grew its position in Synergy Pharmaceuticals by 11.2% in the second quarter. Principal Financial Group Inc. now owns 41,507 shares of the biopharmaceutical company’s stock valued at $185,000 after acquiring an additional 4,164 shares during the last quarter. Finally, Advisor Group Inc. grew its position in Synergy Pharmaceuticals by 25.2% in the second quarter. Advisor Group Inc. now owns 25,625 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 5,150 shares during the last quarter. Institutional investors own 71.47% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.watchlistnews.com/synergy-pharmaceuticals-inc-sgyp-trading-down-nan/1629008.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.